Drug intelligence / Profile preview

incobotulinumtoxinA

Development stage
Approved
Lead developer
Merz
Modality
Recombinant Proteins and Enzymes
Administration
Intramuscular, Intraglandular
01

Overview

IncobotulinumtoxinA is a purified form of botulinum toxin type A, produced by the bacterium *Clostridium botulinum*. It acts as a neuromuscular blocker and is used to treat several conditions involving muscle overactivity or excessive glandular secretion. Its mechanism involves inhibiting the release of acetylcholine at presynaptic nerve terminals, thereby reducing muscle contractions or glandular activity. IncobotulinumtoxinA is indicated for chronic sialorrhea (excessive drooling), upper limb spasticity in adults and children (excluding those with cerebral palsy), cervical dystonia (spasmodic torticollis), blepharospasm (eyelid spasms), and temporary improvement of moderate to severe upper facial lines such as glabellar lines, forehead lines, and crow’s feet in adults[1][3][4][5][6][7].

Brand names
Xeomin
Other names
botulinum toxin type A (purified neurotoxin complex, free from complexing proteins)
02

Targets

GD3 (Ganglioside GD3)SNAP25 (Synaptosome-associated protein 25)SV2A (Synaptic vesicle glycoprotein 2A)

Beyond the preview

Go deeper on incobotulinumtoxinA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on incobotulinumtoxinA.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call